Johnson & Johnson $JNJ is Brandywine Global Investment Management LLC’s 2nd Largest Position

Brandywine Global Investment Management LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,951,088 shares of the company’s stock after selling 3,290 shares during the period. Johnson & Johnson accounts for 2.7% of Brandywine Global Investment Management LLC’s holdings, making the stock its 2nd biggest position. Brandywine Global Investment Management LLC’s holdings in Johnson & Johnson were worth $403,778,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Manchester Capital Management LLC raised its holdings in Johnson & Johnson by 3.8% in the 4th quarter. Manchester Capital Management LLC now owns 22,386 shares of the company’s stock valued at $4,633,000 after acquiring an additional 820 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $2,106,000. IMA Advisory Services Inc. grew its holdings in shares of Johnson & Johnson by 0.9% in the fourth quarter. IMA Advisory Services Inc. now owns 10,288 shares of the company’s stock valued at $2,129,000 after purchasing an additional 94 shares during the period. Endeavor Private Wealth Inc. increased its position in Johnson & Johnson by 8.8% during the fourth quarter. Endeavor Private Wealth Inc. now owns 2,559 shares of the company’s stock worth $530,000 after purchasing an additional 206 shares during the last quarter. Finally, Clearbridge Investments LLC raised its stake in Johnson & Johnson by 5.1% during the fourth quarter. Clearbridge Investments LLC now owns 5,609,012 shares of the company’s stock worth $1,160,785,000 after purchasing an additional 273,320 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $232.81 on Monday. The business has a 50-day simple moving average of $231.98 and a 200-day simple moving average of $226.15. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a one year low of $149.04 and a one year high of $251.71. The company has a market cap of $560.42 billion, a PE ratio of 26.91, a P/E/G ratio of 2.28 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter in the previous year, the firm earned $2.77 earnings per share. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be given a dividend of $1.34 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, April 24th. Argus increased their price objective on Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Royal Bank Of Canada reissued an “outperform” rating and set a $265.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Finally, Morgan Stanley set a $283.00 target price on Johnson & Johnson in a research report on Wednesday, April 15th. Twenty investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer highlighted Johnson & Johnson’s lack of major patent expirations and pointed to its billion-dollar drugs and growing businesses as reasons to own the stock. Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations
• Positive Sentiment: ASCO 2026 updates underscored Johnson & Johnson’s expanding specialty-drug pipeline, with encouraging data in autoimmunity, oncology, and myeloma that could support longer-term revenue growth. ASCO 2026 Data Underscore Johnson & Johnson’s Expanding Specialty Drug Story
• Positive Sentiment: Separate market coverage noted Johnson & Johnson has been outperforming the broader market recently, reinforcing investor confidence in the defensive healthcare name. Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
• Neutral Sentiment: Newsweek named Johnson & Johnson among the world’s greenest companies for 2026, which is supportive for ESG-focused investors but unlikely to move the stock on its own. Goldman Sachs, Johnson & Johnson, MetLife Named Among Newsweek’s World’s Greenest Companies 2026
• Neutral Sentiment: Analysts highlighted ongoing headwinds, including Stelara erosion, China MedTech pressure, and talc litigation, though J&J is still targeting $100 billion in revenue and faster growth in 2026. Can JNJ Sustain Growth Amid Patent, Legal and China Risks?

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.